Fp-21399 blocks hiv envelope protein-mediated membrane fusion and concentrates in lymph nodes

Nature Biotechnology

Volumn 15, Issue 4, 1997, Pages 343-348

  Ono, Mitsunori ^a   Wada, Yumiko ^a   Wu, Yaming ^a   Nemori, Ryoichi ^b   Jinbo, Yumiko ^b   Wang, Hong ^a   Lo, Kin Ming ^a   Yamaguchi, Naoto ^a   Brunkhorst, Beatrice ^a   Otomo, Hiroko ^b   Wesolowski, John ^a   Way, Jeffrey C ^a   Itoh, Isamu ^b   Gillies, Stephen ^a   Chen, Lan Bo ^c  

^a Fuji ImmunoPharmaceuticals Corp   (United States)

^b FUJIFILM CORPORATION   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FP 21399; MEMBRANE PROTEIN; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL SPECIFICITY; HUMAN IMMUNODEFICIENCY VIRUS; LYMPH NODE; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TARGET CELL; VIROGENESIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ANIMALS; ANTI-HIV AGENTS; BIOTECHNOLOGY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHLOROBENZENES; DOGS; DRUG RESISTANCE, MICROBIAL; GENE PRODUCTS, ENV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LYMPH NODES; MALE; MEMBRANE FUSION; MICE; MICE, SCID; NAPHTHALENES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; VARIATION (GENETICS);

EID: 0030892224     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0497-343     Document Type: Article

References (38)

1. Rusche, J.R., Jahaverian, K., McDanal, C, Petro, J., Lynn, D.L, Grimalla, R., et al. 1988. Antibodiea that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Nat. Acad. Sci. 86:3198–3202.
2. Palker, T.J., Clark, M.E., Langlois, A.G., Matthews, T.J., Weinhold, K.J., Randall, R.R., et al. 1988. Type-specific neutralizatlon of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Nat. Acad. Sci. 85:1932–1936.
3. Matsushita, S., Robert-Guroff, M., Rusche, J., Koito, A., Hattori, T, Hoshino, H., et al, 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 82:2107–2114.
4. Skinner, M.A., Ting, R., Langlois, A.J., Weinhold, K.J., Lyerly, H.K., and Matthews, T.J. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses 4:187–194.
5. Kinney-Thomas, E., Weber, H.N., McClure, J., Clapham, P.R., Singhal, M.C., Shiver, M.K., et al. 1988. Neutralizing monoolonal antibodies to the AIDS virus. AIDS 2:25–29.
6. Chang, R.S., Tabba, H.D., He, Y, and Smith, K.M. 1988. Dextran sulfate as an inhibitor against the human immunodeficiency virus. Proc. Soc. Exp. Biol. Med. 189:304–309.
7. Callahan, L.N., Phelan, M., Mallinson, M., and Noroross, M.A. 1991. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type I without interfering with gp120-CD4 interactions. J. Virol. 65:1543–1550.
8. Baitinic, D. and Robey, F.A. 1992. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J. Biol. Chem. 267:6664–6671.
9. Levine, A.M., Gill, P.S., Cohen, J., Hawkins, J.G., Formenti, S.C., Aguilar, S., et al. 1986. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann. Intern. Med. 105:32–37.
10. Aoki, T., Kaneko, Y, Nguyen, T., Stefanski, M.S., Ting, R.C.Y, and Manak, M.M. 1992. Curdlan sulfate and HIV-1: II. In vitro long-term treatment of HIV-1 infection with curdlan sulfate. AIDS Res. Hum. Retroviruses 8:605–613.
11. Cardin, A.D., Smith, P.L, Hyde, L, Blankenship, D.T., Bowlin, T.L, Schroeder, K., et al. 1991. Stilbene disuifonic acids: CD4 antagonists that block human immunodeficiency virus type-1 growth at multiple stages of the virus life cycle. J. Biol. Chem. 266:13355–13363.
12. Clanton, D.J., Moran, R.A, McMahon, J.B., Weislow, O.S., Buckheit, R.W.J., Hollingshead, M.G., et al. 1992. Sulfonic acid dyes: inhibitlon of the human immunodeficiency virus and mechanism of action. J. AIDS 5:771–781.
13. Wyatt, J.R., Vickers, T.A., Roberson, J.L., Buckheit, R.W.J., Klimkait, T, DeBaets, E, et al. 1994. Combinatorially selected guanosine-quartet structure is a potent Inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. 91:1356–1360.
14. Mohan, R, Sun, D., Thornton, A, and Sari, P.S. 1990. Inhibition of HIV replication by derivatives of naphthalenedisulfonic acids. AIDS 4:821–822.
15. Mohan, R, Singh, R., and Baba, M. 1991. Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2. J. Med. Chem. 34:212–217.
16. Flexner, C, Barditch-Crovo, PA, Kornhauser, D.M., Farzadegan, H., Nerhood, LJ., Chaisson, R.E., et al. 1991. Pharmacokinetics, toxicity, and activity of intra-venous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. 36:2544–2550.
17. Feng, Y, Broder, C.C, Kennedy, P.E., and Berger, EA 1996. HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane, G proteln-coupled receptor. Science 272:872–877.
18. Deng, H.-K., Liu, R., Ellmeler, W., Choe, S., Unutmaz, D., Brukhart, M., et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666.
19. − cells Is mediated by the chemokine receptor CC-CKR-5. Nature 381:67–673.
20. Doranz, B.J., Rucker, J., Yanjie, Y, Smyth, R.J., Samson, M., Peiper, S.C., et al. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the B-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149–1158.
21. Choe, H., Farzan, M., Sun, Y, Sullivan, N., Rollins, B., Ponath, P.D., et al. 1996. The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 Isolates. Cell 88:1185–1148.
22. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and Markowitz, M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126.
23. Wei, X., Ghosh, S.K, Taylor, M.E., Johnson, V.A., Emini, EA, Deutsch, R, et al. 1995. Viral dynamics In human immunodeficiency virus type 1 infection. Nature 373:117–122.
24. Embretson, J., Zupancic, M., Ribas, J.L., Burke, A., Racz, R, Tenner-Racz, K., et al. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359–362.
25. Pantaieo, G., Graziosi, C, Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., et al. 1993. HIV infection is active and progressive in Iymphoid tissue during the clinically latent stage of disease. Nature 362:355–358.
26. Fauci, A. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011–1018.
27. Traunecker, A., Luke, W., and Karjaiainen, K. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 331:84–86.
28. Smith, D.H., Bym, R.A., Marsters, SA, Gregory, T, Groopman, J.E., and Capon, D.J. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 236:1704–1707.
29. Hussey, R.E., Richardson, N.E., Kowalski, M., Brown, N.R., Chang, H.-C, Siliciano, R.F., et al. 1988. A soluble CD4 protein selectively inhibits HIV replication and syncitium formation. Nature 331:78–81.
30. Thali, M., Furman, C, Helseth, E., Repke, H., and Sodroski, J. 1992. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J. Vlrol. 66:5516–5524.
31. Lin, P.-R, Simanta, H., Bechtold, C.M., Deminie, CA., Patick, A.K, Alam, M., et al. 1996. Characterization of siamycin I, a human Immunodeficiency virus fusion inhibitor. Antimicrob. Agents Chemother. 40:133–138.
32. Uryu, T, Kaneko, Y, Yoshida, T, Mihara, R., Shoji, T, Katsuraya, K., et al. 1993. pp. 101–115 in Carbohydrates and carbohydrate polymers: analysis, biotechnol, modification, antiviral, biomedical, and other applications. Yalpani, M. (ed.). ATL Press, Shrewsbury, MA.
33. McCune, J.M., Namikawa, R., Shih, C.C., Rabin, L, and Kaneshima, H. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:564–566.
34. Romero, D.L., Busso, M., Tan, C.K., Reusser, F, Palmer, J.R., Poppe, S.M., et al. 1991. Non-nucleoside reverse transcriptase Inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. 88:8806–8810.
35. Japour, A.J., Mayers, D.L., Johnson, V.A., Kuritzkes, D.B., Beckett, LA., Arduino, J.-M., et al. 1993. The RV-43 Study Group, and The ACTG Virology Committee Resistance Working Group. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type I isolates. Antimicrob. Agents Chemother. 37:1095–1101.
36. Douglaa, S.D. and Hassan, N.F. 1990. pp. 858–868? in Hemotology. Williams, W.J., Beutler, E., Erslev, A.J., and Lichtman, M.A. (eds). McGraw-Hill, New York.
37. Ashorn, PA, Berger, EA, and Moss, B. 1990. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J. Virol. 64:2149–2156.
38. Mosier, D.E., Gulizia, R.J., Baird, S.M., Wilson, D.B., Spector, D.H., and Spector, S.A. 1991. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791–794.